Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.7% |
| 2 | Financials | 7.47% |
| 3 | Consumer Discretionary | 6.7% |
| 4 | Communication Services | 6.02% |
| 5 | Healthcare | 4.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
4026
TriSalus Life Sciences
TLSI
$352M
| $333K | ﹤0.01% |
47,699
+21,231
| +80% | +$119K |
|
4027
BK Technologies
BKTI
$292M
| $332K | ﹤0.01% |
4,445
+150
| +3% | +$10.7K |
|
4028
Park-Ohio Holdings
PKOH
$716M
| $331K | ﹤0.01% |
15,828
+1,640
| +12% | +$34.1K |
|
4029
VTEX
VTEX
$660M
| $330K | ﹤0.01% |
87,792
+5,169
| +6% | +$21.2K |
|
|
ACH
4030
Accendra Health
ACH
$93.1M
| $329K | ﹤0.01% |
117,603
+7,536
| +7% | +$26.9K |
|
|
HERE
4031
Here Group Ltd
HERE
$102M
| $329K | ﹤0.01% |
64,368
-72,166
| -53% | -$445K |
|
|
OLPX
4032
DELISTED
Olaplex Holdings
OLPX
| $328K | ﹤0.01% |
245,088
+21,292
| +10% | +$25.3K |
|
|
SOLS
4033
PUT
Solstice Advanced Materials
SOLS
$9.88B
| $328K | ﹤0.01% |
+6,750
| New | +$318K |
|
4034
Superior Group of Companies
SGC
$213M
| $328K | ﹤0.01% |
33,873
+1,632
| +5% | +$15.9K |
|
4035
Hamilton Beach Brands
HBB
$443M
| $328K | ﹤0.01% |
19,930
+830
| +4% | +$12.6K |
|
|
DAWN
4036
PUT
DELISTED
Day One Biopharmaceuticals
DAWN
| $326K | ﹤0.01% |
+35,000
| New | +$292K |
|
|
KDK
4037
Kodiak AI
KDK
$829M
| $323K | ﹤0.01% |
29,597
-91,684
| -76% | -$734K |
|
4038
Rocky Brands
RCKY
$356M
| $323K | ﹤0.01% |
11,006
+1,061
| +11% | +$31.2K |
|
4039
Nano X Imaging
NNOX
$71M
| $323K | ﹤0.01% |
115,284
+24,822
| +27% | +$89.2K |
|
4040
Gilat Satellite Networks
GILT
$895M
| $323K | ﹤0.01% |
+24,945
| New | +$320K |
|
|
NREF
4041
NexPoint Real Estate Finance
NREF
$317M
| $322K | ﹤0.01% |
22,858
+951
| +4% | +$13.3K |
|
4042
ProShares Short VIX Short-Term Futures ETF
SVXY
$235M
| $322K | ﹤0.01% |
5,810
| – | – |
|
|
RJET
4043
Republic Airways Holdings
RJET
$962M
| $321K | ﹤0.01% |
+17,500
| New | +$364K |
|
4044
CuriosityStream
CURI
$166M
| $321K | ﹤0.01% |
84,538
+29,971
| +55% | +$133K |
|
4045
Spire Global
SPIR
$571M
| $321K | ﹤0.01% |
42,784
+626
| +1% | +$6.12K |
|
4046
ProShares VIX Short-Term Futures ETF
VIXY
$189M
| $321K | ﹤0.01% |
12,500
| – | – |
|
4047
Alico
ALCO
$308M
| $320K | ﹤0.01% |
8,795
+1,278
| +17% | +$44.5K |
|
|
ARDT
4048
Ardent Health
ARDT
$1.57B
| $319K | ﹤0.01% |
36,137
+812
| +2% | +$9.39K |
|
|
CD
4049
Chaince Digital Holdings
CD
$328M
| $318K | ﹤0.01% |
64,068
+19,020
| +42% | +$220K |
|
4050
AMES National
ATLO
$281M
| $317K | ﹤0.01% |
13,806
-2,076
| -13% | -$44.6K |
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $49.1B in Q4 2025, closing 641 positions and reducing 1,715 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.